Dr. Joshua Meeks joins the podcast to give a stellar overview of emerging data in the NMIBC space.
The Uromigos: Bladder Cancer
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, discuss research and news on bladder cancer.
Advertisement
Dr. Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1.
Dr. Mark Tyson from Mayo Clinic joins the podcast to discuss the high CR rate seen in cohort C of the BOND-003 trial.
Dr. Neal Shore joins the show to discuss exciting data from the CREST trial.
Dr. Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer.
Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer.
Brian and Tom discuss the new Uromigos Score which ranks different treatment options in several urothelial cancer settings.
Dr. Gopa Iyer of Memorial Sloan Kettering Cancer Center joins the show to discuss his initial results.
Dr. Matt Galsky joins the show to discuss pathological complete response rates from the NIAGARA trial.
Dr. Xinan Sheng joins the podcast to discuss the update of this trial and impressive pCR rates.
Romain Banchereau, PhD, joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in UC.
Dr. Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer from 2024.
Jonathan Rosenberg joins the podcast to discuss new updates on the phase 3 TROPiCS-04 study.
Dr. Bishoy Faltas of Weill Cornell Medicine joins us to discuss his work on extrachromosomal DNA in bladder cancer.
Christopher Cutie from J and J joins the show to discuss the SUNRISE bladder program.
Drs. Maite Bourlon, Elena Castro and Cristina Suarez cover the UC topics discussed on day 1 of Uromigos Live 2024.
Listen to the podcast format of the peri-operative therapy in bladder cancer panel from Uromigos Live 2024.
Listen to the podcast format of the panel on on emerging ADC data in bladder cancer from Uromigos Live 2024.
Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024.
Fresh off the Presidential session address, Tom discusses his data with Petros commenting.
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotin + pembrolizumab in bladder cancer.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon discuss recent ESMO guideline changes on GU cancers.
Dr. Jonathan Rosenberg discusses the treatment-related side effects of EV/pembro for bladder cancer.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon host the first Spanish-language ASCO episode for The Uromigos.
Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup.
Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round.
Dr. Aditya Bagrodia discusses new drugs and studies for NMIBC that were presented at this year's AUA meeting.
Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup.
Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
Tom and Brian are joined by David Penson to discuss upcoming presentations to look forward to at AUA.
Alison Birtle gives an update on the POUT trial on the use of adjuvant chemotherapy after nephroureterectomy for UTUC.
Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer.
Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.
Michiel Van der Heijdan explores the role of radiotherapy and other neoadjuvant combinations for MIBC.
Dr. Galsky discusses his phase 2 study evaluating the effects of gem/cis/nivo followed by nivolumab in responders.
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
Andrea Apolo, MD, discusses the phase III AMBASSADOR study that investigated adjuvant pembrolizumab against observation.
Elena Castro, Begoña Valerrama and Cristina Suárez analyze some of the urothelial carcinoma research highlights of 2023.
Dr. Kala Sridhar joins the podcast to discuss updates and advancements in the bladder cancer field in 2023.
Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches.
Dr. James Catto joins the podcast to compare robotic cystectomy against open cystectomy for patients with bladder cancer.
Ananya Choudhury explains trimodality therapy for bladder cancer and myths around trimodal therapy and radical cystectomy.
Matt Galsky, MD, talks about his new ctDNA study as well as how ctDNA may play a role in upcoming neoadjuvant trials.
Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC.
Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023 on the CONTACT-03 trial and the EV-103 trial.
Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC.
Sia Daneshmand, MD, reviews 2 studies on the use of erdafitinib for the treatment of NMIBC, including the THOR-2 trial.
The Uromigos are joined by Kala Sridhar, MD, to discuss the PET MUSE study on the impact of PET imaging in MIUC.
Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium.
Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.
Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the IMvigor130 study.
Andrea Necchi, MD describes the results of the phase 2 KEYNOTE-057 study at the 2023 ASCO GU Cancers Symposium.
Vadim Koshkin, MD, discusses the prevalence of HER2 expression in bladder cancer and the UNITE study for advanced UC.
Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer.
A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference.
Sam Chang, MD, MBA, joins The Uromigos to discuss the results of IL-15RαFc superagonist N-803 for papillary NMIBC.
Is cisplatin any different from carboplatin in advanced bladder cancer? The Uromigos debate the topic with Matt Galsky, MD.
Dr. Andrea Necchi describes his recent phase 2 study on the use of neoadjuvant pembrolizumab and nab-paclitaxel for MIBC.
The Uromigos chat with Cora Sternberg on her paper on FGFR inhibition in advanced urothelial cancer.
John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.
Cora Sternberg, MD, discusses her career that has spanned multiple continents.
Syed Hussain and Sam Funt describe their studies on this topic.
Matt Galsky and Tom Powles take the FDA and EMA approach respectively concerning adjuvant nivolumab for bladder cancer.
Cisplatin-based combination chemotherapy is considered standard of care in mUC, but many patients are deemed ineligible.
Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial.
Dr. Joaquim Bellmunt gives an overview of the updated ESMO guidelines on bladder cancer.
Jonathan Rosenberg discusses what happened in the world of bladder cancer during 2021 and what to look out for in 2022.
Dr. Arjun Balar discusses bladder cancer, clinical trials involving pembrolizumab, and his career transition.
Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom.
Dr. Jonathan Rosenberg gives an overview of the NORSE Study.
Dr. Dean Bajorin discusses developments in bladder and collaboration in testis cancer.
Dr. Ashish Kamat walks through ongoing issues around surgery in urothelial cancer at EAU 2021.
Join the debate around pembrolizumab monotherapy in initial treatment of cisplatin-ineligible metastatic urothelial cancer.
Arjun Balar explains why, despite a negative trial, T cell stimulation plus checkpoint inhibition may warrant future study.
Matt Gowski takes a deeper dive into the phase 2 data of neoadjuvant chemo/nivolumab in muscle-invasive bladder cancer.
The Uromigos and Andrea Necchi have a wide-ranging discussion of 3 interesting neoadjuvant IO-based phase 2 trials.
Dr. Lydia Makaroff, Vice President of the World Bladder Cancer Patient Coalition, discusses key issues for bladder cancer.
Dr. Petros Grivas discusses the accelerated approval of sacituzumab govitecan in bladder cancer.
Dr. Andrea Apollo discusses highlights from the ODAC meeting regarding accelerated approvals for bladder cancer.
Dr. Jorge Garcia discusses ODAC meetings on bladder cancer and the "dangling accelerated approvals" that resulted.
Dr. Joaquim Bellmunt describes this study, as well as adjuvant nivolumab and ctDNA in bladder cancer.
Dr. Noah Hahn discusses ASCO GU Symposium 2021 data on the cisplatin-ineligible PD-L1 positive population.
Matt Galski discusses this potentially practice-changing study.
Dr. Arjun Balar discusses these studies and the impact they will have.
Matt Galsky conducts a year in review discussion on bladder cancer, including first-line and adjuvant immune therapy studies.
Drs. Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer.
Dr. Peter O'Donnell and Prof. Tom Powles debate front-line treatment options in urothelial cancer.
Dr. Richard Cathomas goes into the detail of chemo immune combinations and what to do next.
Matt Galsky tries to get to the bottom of whether these data has made any difference in treatment and future plans.
Tom, Brian, and Chris Sweeney discuss the challenges of development of biomarkers for immune therapy in bladder cancer.
Dr. Jürgen Gschwend discusses German research and surgery for bladder cancer.
Dr. Peter Black talks about his BCG refractory NMIBC presentation at ASCO 2020 and its implications for the field.
The Uromigos Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC With Jonathan Rosenberg
The Uromigos and Dr. Jonathan Rosenberg discuss everything you wanted to know about FGFR inhibition but were afraid to ask.Dr. Tian Zhang discusses 3 ASCO 2020 bladder cancer abstracts with immune therapy/targeted therapy combinations.
Dr. Kala Sridhar, Professor Tom Powles, and Dr. Brian Rini discuss the data presented at ASCO 2020.
Joaquim Bellmunt explains why this trial was not successful and what it means for the field.
Joaquim Bellmunt talks about management of muscle invasive bladder cancer prior to the Atezolizumab adjuvant data at ASCO20.
The Uromigos talk to Dr. Kala Sridhar about key developments in urothelial cancer presented at ASCO GU 2020.
Dr. Arjun Balar and Dr. Seth Lerner give an overview of the FDA approval of pembrolizumab in this indication.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.